Overview of Feri

Feri is a specialized pharmaceutical preparation containing the active ingredient Folic Acid, which is the synthetic form of the essential micronutrient Folate, or Vitamin B9. It is structurally classified as a single-ingredient product, provided most commonly as an Oral formulation in the form of Tablets, intended to correct or prevent specific nutritional deficiencies.

Property	Description
Active ingredient	Folic Acid (Pteroylglutamic Acid)
Form	Tablets (Oral formulation)
Pharmacological class	Hematopoietic Agent, Antianemic Preparation
Common purpose	Addresses deficiency states affecting cell production
Origin	Synthetic (Pteroylglutamic Acid)

What Type of Medicine is Feri?

The medicine Feri is fundamentally classified as a Hematopoietic Agent and an Antianemic Preparation. This classification signifies its primary function is to support the creation and maturation of blood cells. The compound itself is an Essential Nutrient, which the human body cannot synthesize in adequate amounts and must be obtained through supplementation. Feri, often available over-the-counter (OTC) at certain lower doses, is positioned primarily toward addressing dietary insufficiency and supporting the metabolic processes throughout the body.

Composition, Origin, and Dosage Form

The core of Feri's composition is its active ingredient, Folic Acid, or Pteroylglutamic Acid. This compound is synthetic in origin, a property that grants it superior chemical stability and increased bioavailability compared to the naturally occurring Folates found in food. Synthetic Folic Acid, like that in Feri, is the highly absorbable form used in supplements for deficiency prevention. This synthetic component is combined with standard solid oral excipients to produce the final, consistently dosed Tablet for reliable Oral administration.

General Purpose and Essential Benefit

Feri's essential benefit is derived from its indispensable role in key cellular reactions, including the synthesis of DNA and other nucleoproteins. By providing this necessary cofactor, Feri supports erythropoiesis, the complex physiological process responsible for generating mature red blood cells. This action is integral to preventing the pathological states associated with severe Folate deficiency. Therefore, the overall general purpose of the preparation is to ensure the body possesses the foundational material required to maintain robust cellular regeneration and prevent disruptions in blood cell formation.

What side effects are possible with Feri?

Possible Side Effects and Safety Information

Feri, containing the active ingredient Folic Acid, has an official safety profile that is generally considered minimal at standard therapeutic doses. Regulatory documents classify the occurrence of most adverse reactions as Rare or Very Rare.

Adverse Reactions and Frequencies

Adverse reactions documented in official regulatory labeling are primarily associated with the Immune System, Skin, and Gastrointestinal Disorders. The vast majority of documented effects fall under the Rare frequency tier (occurring in less than 1 in 1,000 patients).

System-Organ Class	Examples of Documented Effects (Typically Rare)
Gastrointestinal Disorders	Nausea, abdominal distension, flatulence, loss of appetite.
Skin and Immune Disorders	Rash, pruritus (itching), erythema.

Serious adverse reactions, such as Anaphylaxis and severe allergic responses, are formally documented in official prescribing information but are categorized as Very Rare events.

Key Regulatory Safety Limitation

The most significant safety constraint noted in government regulatory documents is the risk of masking symptoms of Pernicious Anaemia (Vitamin B12 deficiency). The medicine may correct the blood count abnormalities associated with this condition, which can delay the diagnosis and allow the associated neurological damage to continue progressing. This represents a critical safety consideration for the appropriate clinical use of Feri, as specified in regulatory labeling.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Feri

Overdose scope Documented overdose presentations: Overdose of Feri, which involves excessive iron exposure, can lead to severe systemic toxicity. Initial symptoms may include severe abdominal pain, vomiting, and diarrhea. These effects can progress to signs of cellular damage, including low blood pressure (shock), metabolic acidosis, and seizures. Delayed manifestations can include liver damage or failure and the development of gastrointestinal strictures weeks later. Physiological systems affected (as stated in label): Gastrointestinal System, Hepatic System (Liver), Cardiovascular System (Circulatory/Shock), and Central Nervous System. Dose-related or exposure-related factors (if applicable): Overdose typically occurs following the intake of a toxic quantity of the substance. Severe outcomes are more likely with higher levels of exposure.

Emergency-response statements (as written in official documents): When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention by calling 9-1-1 or a certified Poison Control Center (1-800-222-1222) if an overdose is suspected. This action is required if an individual has collapsed, is having a seizure, is experiencing severe difficulty breathing, or cannot be awakened.

Overdose classifications (high-level) Severity classification (as defined in official documents): Classified as a potentially severe and fatal poisoning due to the risk of irreversible organ damage, particularly to the liver and gastrointestinal tract. Regulatory basis (EMA / FDA / etc.): Authoritative medical and toxicological guidance from regulatory and public health bodies on managing acute iron toxicity.

Resulting overdose structure Official overdose statements:

Overdose is an acute, life-threatening situation requiring immediate medical intervention.
The clinical course of overdose is often staged, with initial gastrointestinal symptoms followed by a period of apparent improvement, which may then progress to severe organ failure.
Treatment involves supportive care and specialized interventions such as iron chelation therapy to remove excess iron from the body.

Connection to the overall overdose profile (2–4 sentences): Regulatory information defines the overdose profile of high-dose iron exposure as a severe, multi-system toxic event with the potential for fatal outcomes. The initial gastrointestinal distress is a crucial early marker, but the profile emphasizes the risk of delayed yet severe complications, such as liver failure and shock, requiring hospital-based care and advanced treatments like chelation. Prompt reporting to emergency services is mandated due to the high severity classification.

Therapeutic Uses of Feri

Main Uses of Feri

Feri is an iron-based medication primarily used for the treatment of iron deficiency and iron deficiency anemia. It is specifically indicated for patients who require a rapid increase in iron levels or for those who cannot tolerate or have not responded adequately to oral iron supplements.

The medication works by replenishing the body's iron stores, which are essential for the production of hemoglobin. Hemoglobin is the protein in red blood cells that enables them to carry oxygen throughout the body. When iron levels are low, the body cannot produce enough healthy red blood cells, leading to various physical symptoms.

Iron Deficiency Anemia

In cases of iron deficiency anemia, Feri is used to restore iron levels to a healthy range. This condition often occurs due to chronic blood loss, increased demand during specific life stages, or inadequate absorption of iron from the diet. By delivering iron directly into the system, the medication helps facilitate the recovery of red blood cell counts and hemoglobin concentration.

Non-Anemic Iron Deficiency

Feri may also be used in patients who have low iron stores but have not yet developed clinical anemia. Treating iron deficiency at this stage can help prevent the progression to anemia and address symptoms associated with depleted iron reserves.

Benefits of Treatment

The primary benefit of treatment with Feri is the restoration of normal iron levels, which supports several vital physiological functions.

Improved Energy and Physical Function

As iron levels and hemoglobin concentrations normalize, the body's ability to transport oxygen improves. This often results in a reduction of symptoms such as:

Persistent fatigue and exhaustion
Shortness of breath during physical exertion
General physical weakness

Cognitive and Psychological Well-being

Adequate iron levels are necessary for proper brain function. Patients undergoing treatment may experience improvements in concentration, mental clarity, and mood stabilization as iron stores are replenished.

Support for Organ Systems

Iron is a component of various enzymes and myoglobin, which is responsible for storing oxygen in muscle tissues. Ensuring sufficient iron levels supports overall muscle metabolism and the healthy functioning of various organ systems that rely on iron-dependent processes.

Eligibility and Restrictions for Use

The eligibility profile for Feri (Folic Acid) is defined by official regulatory documentation, specifying the populations permitted, restricted, or prohibited from using the medicine.

Eligibility Scope	Status Defined by Regulators
Contraindicated Populations	Individuals who have demonstrated a known hypersensitivity or intolerance to the active substance or any non-active component of the formulation.
Absolute Restriction	Must not be administered as a single-agent treatment for undiagnosed megaloblastic anemia or pernicious anemia (due to Vitamin B12 deficiency).
Age-Related Eligibility	Use is permitted across the entire age spectrum, including pediatric, adult, and geriatric populations.
Pregnancy and Lactation	Use is permitted and officially recommended for women of childbearing potential, including individuals who are pregnant or who are breastfeeding.
Conditional Use Groups	Patients with a confirmed Vitamin B12 deficiency may use Feri only under the condition that they are simultaneously receiving adequate treatment for the B12 deficiency.

The most critical regulatory constraint defining non-eligibility is the requirement for a definitive diagnosis of the underlying anemia. This strict rule prohibits Feri from being used alone in Vitamin B12 deficiency, as doing so may mask the hematological signs while allowing unchecked neurological damage to progress. Patients taking certain anticonvulsant medications may also fall under conditional use rules as noted in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Feri, which contains Folic Acid, has officially documented interaction patterns primarily concerning its role in metabolism and its relationship with drugs that interfere with folate pathways. All interaction information is based strictly on regulatory sources.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Category	Interacting Medicinal Products or Substances
Pharmacokinetic Interactions (Exposure Reduction)	Folic Acid co-administration has been officially reported to reduce the plasma concentrations of certain anticonvulsants, including Phenytoin, Phenobarbital, and Primidone.
Pharmacodynamic Antagonism	Folic Acid is documented to antagonize the action of Folate Antagonists (e.g., Methotrexate, Trimethoprim, Pyrimethamine), resulting in a reduction of their therapeutic efficacy. Chloramphenicol may also produce an antagonistic hematologic response to Folic Acid therapy.

Absorption- and Metabolism-Modifying Factors

Regulatory documents identify specific agents that affect Folic Acid levels or absorption:

Sulfasalazine is officially documented to reduce the absorption of Folic Acid.
Long-term use of Oral Contraceptives may lead to reduced serum folate levels.
Chronic, high alcohol intake is officially recognized to interfere with folate metabolism and reduce absorption, thus increasing the requirement for Folic Acid.

Interaction-Specific Regulatory Notes

In the context of deficiency treatment, the regulatory documentation notes that the risk or severity of Folic Acid needs must be considered in patients with Renal Dialysis or Chronic Alcohol Intake due to altered loss or absorption.

Mechanism of Action

The Mechanism of Folic Acid: Metabolic Co-factor Provision

Feri, supplying Folic Acid, operates purely as a precursor, initiating a fundamental metabolic cascade. The inactive Folic Acid is enzymatically converted, primarily by Dihydrofolate Reductase (DHFR), into the active co-factor, Tetrahydrofolate ( THF). THF functions as a carrier and donor of one-carbon units ( CH3) within the One-Carbon Metabolism Pathway.

The ultimate intracellular consequence is the essential drive of Deoxythymidylate ( dTMP) and Purine synthesis, which are required building blocks for DNA replication. Successful DNA synthesis supports the execution of cell division and nuclear maturation in precursor cells, particularly within the hematopoietic system. This mechanistic action regulates cell morphology, reducing the formation of large, immature megaloblasts at a systemic level.

This mechanism is subject to an obligate co-factor dependency: the recycling of THF requires Vitamin B12 for the enzyme Methionine Synthase. The action influences the mechanisms underlying hematological changes associated with DNA synthesis impairment but does not directly influence separate B12-dependent neurological pathways.

Dosage and Administration Information

Feri is administered primarily via the oral route in tablet form. This is the preferred method for standard regimens, with parenteral (injection) administration reserved for specific clinical scenarios involving severe malabsorption. The tablets can be taken with or without food without affecting the required pattern of use.

The standard regimen for treating folate-deficiency megaloblastic anemia in adults is typically 5 mg once daily. In cases of severe malabsorption or high metabolic need, the dose may be increased, reaching up to 15 mg daily. Frequency is most often once daily, though specific prophylactic use for chronic conditions may follow an intermittent schedule, such as 5 mg every 1 to 7 days.

Use of Feri is often defined by a fixed course duration. Treatment for established anemia usually lasts for a period of four months, after which the regimen may transition to a long-term maintenance approach as needed. When a daily dose is missed, the recommended action is to skip the missed dose and resume the regular schedule the following day, rather than taking a double dose.

Population-specific usage includes a specialized regimen for preventing the recurrence of Neural Tube Defects in high-risk pregnancies, requiring a 5 mg daily dose initiated prior to conception and continued throughout the first trimester. For children (over one year) with megaloblastic anemia, the standard course and daily dose typically mirrors the adult therapeutic dose of 5 mg daily for four months.

Recent Clinical Evidence

Research evidence / Overview of studies for Feri (Folic Acid)

Evidence for use in Folate-Deficiency Anemia

The clinical evaluation of Feri, specifically its active ingredient Folic Acid, has been extensively researched for use in managing a specific type of blood disorder known as folate-deficiency anemia. Studies, including Randomized Controlled Trials (RCTs), was evaluated in adults and children with confirmed deficiency. Research so far describes that following the use of Feri, patterns of change were measured in blood cell parameters, with many studies documenting shifts in the observed ranges. The evidence base highlights that the necessity of excluding a Vitamin B12 deficiency was noted in some studies to prevent potential complications during the research.

Evidence for use in Preventing Neural Tube Defects

The strongest and most substantial body of evidence was studied for Feri around the time of conception. This research involves large-scale Randomized Controlled Trials and extensive observational studies. The studies explored the incidence and recurrence of Neural Tube Defects (NTDs), such as Spina Bifida and Anencephaly, in populations that were evaluated for Feri use. The evidence data show patterns related to observed differences in the rates of both initial occurrence and recurrence of these birth defects, which was studied for Feri use in this critical period.

What is Still Uncertain About Feri's Research Record

Despite being a well-studied compound, certain aspects of Feri's research record remain areas of uncertainty. The consistency of evidence differs across studies, and the follow-up durations were limited in many trials focused on hematological correction. Specifically, there is limited information for long-term outcomes and maintenance. Research also continues to examine the precise effects for specific, narrow subgroups, where data are still emerging and certainty remains low. The available studies help show what has been observed so far in defined research conditions, but this research does not determine whether an individual will respond similarly outside of those specific study conditions.

Key Studies & References

Label: FOLIC ACID tablet (FDA-sourced product label)

Frequently Asked Questions (FAQ)

Common questions about Feri (FAQ)

Q: What are the most commonly reported side effects listed for Feri?

According to official product information, the most frequently reported types of adverse events are related to the digestive system and skin. These often include gastrointestinal discomfort, such as nausea or flatulence, and certain skin reactions like rash or itching. It is important to know that regulatory data classifies these documented effects as generally Rare events, meaning they occur in less than 1 in 1,000 patients.

Q: Are there any specific food items or drinks that interact with Feri?

Official guidance notes that chronic, high consumption of alcohol is documented to interfere with the metabolism and reduce the absorption of the active ingredient. Additionally, certain types of antacids (medicines for indigestion) may reduce the amount of the active ingredient absorbed. Official documents suggest that these products be taken at a separate time from Feri administration.

Q: What does 'contraindication' mean in the context of taking Feri?

A contraindication is a specific health condition or circumstance where the medicine should not be used due to a high risk of harm. According to regulatory documents, Feri is contraindicated if a person has a known hypersensitivity to the drug's components. It is also restricted as a sole treatment for undiagnosed megaloblastic anemia to prevent complications.

Q: Does Feri require a prescription in all countries where it is sold?

The prescription status of Feri often depends on the strength and the intended use. Higher doses that are intended to treat an established deficiency are typically available by prescription only from a healthcare professional. Conversely, many lower-dose forms of the active ingredient are widely available over-the-counter as daily dietary supplements.

Q: Is it typical to feel slightly nauseous when starting Feri?

Nausea is listed in the official prescribing information under Gastrointestinal Disorders. However, this effect is categorized as Rare. Official guidance notes that taking the active ingredient with or just after a meal or snack may help limit potential digestive discomfort.

Q: What is the risk level of Feri described as in official safety documents?

Regulatory documents describe the overall safety profile of Feri at standard therapeutic doses as generally minimal. Most documented adverse reactions are categorized as Rare or Very Rare events. The most critical safety constraint noted by regulators is the risk of the drug masking the symptoms of an underlying Vitamin B12 deficiency.

Q: What are the signs that Feri is working, based on clinical description?

Official summaries of the medication's effects describe a prompt clinical response in blood cell production. Within 2 to 5 days of use, an increase in immature red blood cells, called reticulocytosis, is measurable in the body. While these are clinical indicators, a patient's noticeable improvement in energy levels may take a few weeks.

Q: Is Feri metabolized by the liver, and if so, what are the implications?

The active ingredient in Feri is converted by the liver into its metabolically active form, Tetrahydrofolic Acid. This conversion process is necessary for the drug to function as an essential co-factor in the synthesis of DNA and the promotion of blood cell maturation.

Q: Are there different dose strengths of Feri available?

Yes, the active ingredient in Feri is supplied in multiple tablet strengths to address different needs. Official formulations are available in low doses for general supplementation and in high therapeutic doses (such as 1 mg or 5 mg) specifically for treating established deficiency states.

Q: What kind of monitoring or lab tests are recommended while taking Feri?

Official regulatory documents stress the necessity of confirming the exact cause of anemia before treatment begins. If megaloblastic anemia is suspected, laboratory testing to rule out a Vitamin B12 deficiency is emphasized by regulatory documents. This initial testing is necessary to mitigate the safety risk associated with masking symptoms.

Q: How does Feri affect people with known liver or kidney impairment?

Regulatory notes indicate that the requirement for the active ingredient may be altered in patients undergoing Renal Dialysis due to potential changes in how the body processes it. No specific warnings or contraindications regarding routine, non-severe liver impairment are uniformly documented in prescribing information.

Q: What are the official recommendations if a person experiences an allergic reaction to Feri?

While severe allergic responses are classified as Very Rare events, regulatory guidance provides clear instructions for action. If a person experiences any signs of a serious allergic reaction, such as swelling of the face or difficulty breathing, regulatory guidance emphasizes that immediate emergency medical attention should be sought as a necessary action.

Q: What are the known components of the Feri formulation besides the active ingredient?

Official prescribing documents list the excipients, which are the non-active components used to form the tablet. Examples of these often-listed ingredients include common binding and filling agents such as lactose, microcrystalline cellulose, and magnesium stearate. Individuals with specific sensitivities are directed toward reviewing the full excipient list in the product information.

Q: How quickly can a person expect Feri to start having an effect?

While clinical changes in the blood are often measurable within the first few days of use, the onset of a noticeable subjective improvement for the patient may take longer. According to regulatory guidance, it can take several weeks for the full benefit, such as feeling less tired or symptomatic, to become apparent.

Q: Does Feri have any known interaction warnings with over-the-counter pain relievers?

Official interaction warnings do not typically list major concerns with common over-the-counter pain relievers such as acetaminophen. However, regulatory warnings note that if the patient is taking certain folate-antagonist drugs (like methotrexate), then caution may be advised when using NSAIDs (such as ibuprofen).

Q: Is it safe to use Feri if I am also taking a daily vitamin supplement?

The active ingredient in Feri is often included in various daily vitamin and mineral supplements. Regulatory advice emphasizes that individuals are cautioned not to exceed the total recommended daily intake from all sources. Users should carefully check the ingredients of all their supplements to avoid duplication of this nutrient.

Q: Where can I find the official regulatory prescribing information for Feri?

Official prescribing information is publicly available through governmental regulatory bodies. For example, the United States information can be found via the FDA DailyMed database, and European information is published on the EMA or national regulatory agency websites as a Summary of Product Characteristics (SmPC).

Q: Is it possible for Feri to cause changes in mood or sleep patterns?

While not consistently noted in the safety profile for the standard therapeutic dose, official documentation for related B-vitamins or high doses has mentioned rare reports of effects like insomnia or irritability. Any unusual changes in mood or sleep are recommended by regulators as subjects for consultation with a healthcare provider.

Q: Are there any specific long-term effects mentioned in the drug's safety profile?

Regulatory reports emphasize that the primary long-term risk of Feri is associated with its inappropriate use as a sole treatment for undiagnosed B12 deficiency. If this occurs, it can mask the blood symptoms while allowing unchecked progressive neurological damage to develop.

Q: What is the difference between the brand name and the generic version of Feri?

Regulatory bodies mandate that generic versions must contain the same active ingredient and be of the same strength, quality, and efficacy as the brand-name product. The main differences are typically found in the inactive ingredients (excipients), such as the color, binders, or shape of the tablet.

Q: Does Feri contain common allergens like gluten or lactose?

The official list of non-active components, or excipients, specifies any potential allergens. Official product information for some Feri formulations confirms that they may contain lactose as a filler. Individuals with known allergies are advised to check the specific excipient list for their product, which is included in the official information.

Q: Can Feri interact with herbal remedies like St. John's Wort?

Official regulatory guidance advises users to be cautious when combining Feri with any herbal remedies or supplements, as these combinations are not universally studied. Herbal products may contain components that could interfere with the absorption or metabolic pathway of the active ingredient.

Q: Is Feri approved for use in both men and women?

Yes, official recommended dietary intakes and therapeutic treatment guidelines from regulatory bodies specify appropriate use for both adult men and women. While the medication is often highlighted for use in women of childbearing potential, treatment is defined by the diagnosed deficiency state, which can affect any adult.

Q: What is the official Patient Information Leaflet (PIL) for Feri designed to provide?

The official Patient Information Leaflet (PIL) is a regulatory document created specifically to give the user non-technical, essential information about the medicine. This document summarizes the product's approved use, potential side effects, information on how to take the medicine, and necessary disposal instructions.

Q: Can Feri be stopped abruptly, or does it require gradual discontinuation?

Regulatory documentation advises against stopping the medicine or changing the dosage without first consulting a healthcare professional. While abrupt cessation is not typically associated with immediate withdrawal symptoms, it may allow the underlying deficiency condition to recur or worsen.

Q: Are there any documented drug-to-drug interactions with common mental health medications?

Regulatory documents note specific interactions with certain anticonvulsant medications, such as Phenytoin and Phenobarbital. The active ingredient in Feri may reduce the concentration of these anticonvulsants in the blood, potentially lessening their intended effect.

Q: What evidence is there regarding Feri and driving or operating machinery?

Official prescribing documents generally state that Feri is not expected to impair the ability to drive or safely operate machinery. However, as with any medication, if a user experiences a documented adverse effect such as dizziness or drowsiness, regulatory guidance notes that caution is recommended.

Q: What happens in the body when Feri is no longer needed?

The active ingredient is classified as a water-soluble B vitamin, which means the body does not store it in large quantities. Any amount of the active ingredient that is not needed or used by the body's metabolic processes is excreted primarily through the urine.

How should Feri be stored and disposed of?

How to Store and Dispose of Feri (Folic Acid Tablets)

The storage of Feri tablets is strictly governed by regulatory requirements to maintain product stability. The medication must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product requires protection from moisture and excess heat.

Packaging and Safety

Tablets should remain in the original container with the lid tightly closed to prevent moisture exposure. Consistent with regulatory mandates, the medication must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal guidelines recommend utilizing a community drug take-back program for unused or expired tablets. If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt) in a sealed bag before being placed in the household trash. The tablets must not be flushed down the toilet.

Feri